Printer Friendly

GSK obtains CHMP positive opinion for new indication for Arixtra.

M2 PHARMA-July 23, 2010-GSK obtains CHMP positive opinion for new indication for Arixtra(C)2010 M2 COMMUNICATIONS

23 July 2010 - UK GlaxoSmithKline (LON: GSK) said today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arixtra (fondaparinux), an anti-clotting drug (antithrombotic) for the treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis (SVT) of the lower limbs without concomitant deep-vein thrombosis.

The decision was granted via the centralised filing procedure with Sweden as the rapporteur and France the co-rapporteur. The decision was supported by the results of the CALISTO study (Comparison of Arixtra in lower LImb Superficial vein Thrombosis with placebO), the first study in SVT to show a clinical effect with an anticoagulant treatment versus placebo, the company said.

Fondaparinux is currently approved for use in the EU for the prevention of venous thromboembolic events (VTE), initial treatment of acute deep vein thrombosis (DVT), pulmonary embolism (PE) treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) and for the treatment of ST segment elevation myocardial infarction (STEMI).

((Comments on this story may be sent to

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 23, 2010
Previous Article:Takeda gets nod for additional indication of Takepron Capsules 15 and Takepron OD Tablets 15 in Japan.
Next Article:WHO gives update on H5N1 avian influenza situation in Indonesia.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters